VHT vs XLV

Key Takeaways

• VHT offers broader exposure across ~410 holdings including mid- and small-cap healthcare firms, while XLV focuses on ~60 large-cap S&P 500 healthcare stocks for concentrated mega-cap access.
• Both ETFs are passive index trackers with ultra-low expense ratios—VHT at 0.09% and XLV at 0.08%—ensuring cost efficiency for long-term sector positioning.
• Top holdings overlap significantly (LLY, JNJ, ABBV), but VHT dilutes concentration risk through greater diversification.
• XLV exhibits marginally lower volatility due to its large-cap liquidity, appealing for defensive plays, whereas VHT captures more growth from biotech and smaller innovators.
• In recent market cycles, healthcare's defensive profile has supported relative stability amid sector rotations, with both funds benefiting from pharmaceutical earnings strength.
• XLV dominates liquidity with higher average daily volume, suiting tactical traders, while VHT provides comprehensive sector exposure for buy-and-hold strategies.

Introduction

Healthcare ETFs like VHT and XLV offer targeted exposure to a resilient sector amid ongoing economic uncertainty and sector rotation trends. Both provide alternative avenues within healthcare—VHT through broad market-cap coverage via the MSCI US Investable Market Health Care 25/50 Index, and XLV via large-cap focus on the S&P 500's Health Care Select Sector Index. Investors compare them for defensive positioning, as healthcare demonstrates lower beta (around 0.6) relative to broader equities, driven by aging demographics, innovation in biotech and pharmaceuticals, and steady demand for services. This ETF comparison highlights structural differences to aid allocation decisions in a volatile environment.

Vanguard Health Care ETF (VHT) Overview

The Vanguard Health Care ETF (VHT) is a passive index fund tracking the MSCI US Investable Market Health Care 25/50 Index, encompassing large-, mid-, and small-cap U.S. healthcare stocks under the Global Industry Classification Standard (GICS). It holds approximately 410 stocks, promoting diversification across pharmaceuticals (33%), biotechnology (23%), health care equipment (17%), and life sciences tools (9%). Top holdings include LLY (11.9%), JNJ (9.3%), ABBV (6.2%), MRK (4.8%), and UNH (3.9%), with the top 10 comprising about 50% of assets. The expense ratio is 0.09%, and the fund employs full replication where possible, with sampling for constraints. As a non-diversified fund, it rebalances periodically to match the index, offering broad sector exposure with mid/small-cap growth potential and solid liquidity via average daily volumes around 200,000 shares.

Health Care Select Sector SPDR Fund (XLV) Overview

The Health Care Select Sector SPDR Fund (XLV) passively tracks the Health Care Select Sector Index, comprising healthcare companies from the S&P 500, market-cap weighted with modifications for concentration limits. It maintains around 60 holdings, emphasizing large-caps in pharmaceuticals (37%), health care providers/services (19%), biotechnology (18%), and equipment/supplies (17%). Leading positions are LLY (14.5%), JNJ (10.3%), ABBV (6.9%), UNH (6.7%), and MRK (5.3%), accounting for nearly 60% of assets. With a 0.08% expense ratio, it uses index replication and quarterly rebalancing per S&P methodology. XLV's structure suits high-liquidity trading, evidenced by multi-million share daily volumes and tight bid-ask spreads (0.01%), prioritizing stability from mega-cap leaders.

Industry and Thematic Backdrop

The healthcare sector benefits from structural tailwinds like aging populations boosting demand for services and therapeutics, alongside innovation in AI-driven diagnostics, biotech, and GLP-1 drugs for chronic conditions. Macro drivers include moderating inflation easing cost pressures on providers, potential interest rate stabilization favoring defensives, and capital flows into undervalued healthcare amid tech rotations—ETFs saw record inflows in late 2025. Regulatory scrutiny on pricing and drug approvals persists as a risk, alongside workforce shortages and policy shifts like premium hikes (6-9% projected). Geopolitical stability supports supply chains for pharma/biotech, while sector risks encompass patent cliffs and R&D failures. Both ETFs position investors to navigate this resilient backdrop.

Performance and Positioning Comparison

In recent weeks and months, VHT and XLV have displayed relative stability versus broader markets, with YTD declines milder than cyclicals amid sector rotation to defensives. VHT's broader holdings edged XLV in shorter periods (e.g., 1-month: -0.6% vs. -1.3%; 3-month: -6.6% vs. -7.9%), capturing mid-cap biotech upswings, while XLV's large-cap tilt offers steadier returns over cycles (5-year annualized ~4% similar). Volatility profiles align closely (beta ~0.6, monthly vol ~4%), but XLV's liquidity reduces tracking error. Performance ties to pharma earnings cycles (LLY momentum), interest rate expectations favoring low-beta plays, and healthcare's outperformance in uncertain environments over recent market shifts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to uncover healthcare insights and beyond.

Tickeron AI Verdict

Tickeron’s AI currently favors VHT for its superior diversification (~410 holdings vs. 60), broader growth exposure via mid/small-caps, and consistent trend alignment in recent cycles, despite XLV's slight cost and liquidity edge. VHT's structure enhances risk-adjusted positioning amid sector momentum, with ~65% probability of relative outperformance over 12 months based on observable factors like holdings spread and volatility profiles. This reflects structural strength, not advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations